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nists were used more often as first-line medical therapy.
The probability of first-line success has been estimated at
71.2% for common practice and 72.3% for best practice.
CONCLUSION: Despite higher surgical costs and im-
proved outcomes associated with best practice manage-
ment of POAG as compared with common practice, to-
tal, drug, and medical care costs of best practice were
comparable to those of common practice.
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OBJECTIVES: To determine the cost-effectiveness of the
primary treatment of primary open-angle glaucoma
(POAG) with trabeculectomy versus conventional ther-
apy. METHODS: A four-year incremental cost/quality-
adjusted life year (QALY) model (year 2000 US dollars)
of POAG using a societal perspective; including direct
and indirect costs with a 3% annual discount rate for the
base case. In the Glasgow trial, patients newly diagnosed
with POAG with an intraocular pressure of 26mmHg
and/or with glaucomatous field defects were randomized
to trabeculectomy or conventional therapy (up to three
medications). In the trabeculectomy branch, patients
would either be 1) controlled without extra medication,
2) controlled with extra medication or 3) die from natu-
ral causes. Annual chance nodes for the conventional
were 1) controlled by medication, 2) surgery or 3) death
from natural causes. QALYs were calculated assuming a
decline in utility would accompany loss in visual field. A
65-year old patient with a 5% rate of decline in utility
was used as the base case. Sensitivity analyses were per-
formed on the rate of utility decline, cost of medications,
trabeculectomy cost, and discount rate. RESULTS: For
the base case, the cost of initial trabeculectomy was
$8316 versus $6339 for conventional therapy. The incre-
mental cost was $1977 and the incremental QALY was
0.08, with ICE ratio of $24,830/QALY. CONCLU-
SIONS: Initial trabeculectomy is cost-effective for POAG.
The model was most sensitive to the rate of decline in
utility (2%) and robust to changes in the costs of medi-
cations and trabeculectomy. Limitations include the lack
of long-term clinical and QALY data on glaucoma pa-
tients with different treatments. Currently the standard of
practice in the US is to start with conventional therapy
for patients with moderate or severe glaucoma. Our re-
sults indicate that trabeculectomy may be a cost-effective
option for these patients.
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INTRODUCTION: Crohn’s disease (CD) is a debilitat-
ing chronic disease. It also has economic implications
(both for patient and society). Reduced work (or school)
attendance and continuous need for health care contacts
are two important aspects. Data comparing the impact of
different treatment approaches are scarce. OBJECTIVE:
To assess health care utilisation and absence for work (or
school) in a US setting of patients treated with budes-
onide CIR maintenance therapy compared to patients
with no maintenance treatment (placebo). A societal per-
spective was adopted. METHODS: Data was collected in
a double-blind randomised clinical trial comparing
budesonide CIR 6 mg daily with placebo for a one year
period. Patients, 55 in each group, had CD localised to
the distal ileum and/or the ascending colon and were be-
tween the ages of 18 and 73 (mean 40.3 and 40.5 years).
The collected data included physician visits, different mi-
nor procedures (e.g., radiographic, endoscopic), medica-
tions, hospitalisations and surgical procedures. Number
of days of absence due to symptoms or treatment of the
disease was also collected. All resource utilisation related
to the design of the clinical trial was excluded in order
not to overestimate real health care use and productivity
losses. RESULTS: The budesonide CIR treatment group
had 26.3% fewer physician visits (87.14 vs. 118.27 ns)
and 27% fewer days absent from work or school (311.73
vs. 427.23 days ns). Numerical differences in other vari-
ables were smaller but in favour of budesonide CIR.
CONCLUSION: Treatment with budesonide CIR cap-
sules suggests benefits in terms of reduced health care re-
source utilisation and absence from work (school), that
also could represent favourable cost implications in the
delivery of health care.
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OBJECTIVE:To compare the cost-effectiveness of alter-
native dyspepsia management strategies: (1) H. pylori
testing; if seropositive, providing H. pylori eradication
treatment using oral omeprazole, clarithromycin, and
amoxicillin; (2) empiric antisecretory therapy using ome-
prazole. METHODS: Decision analytical models com-
pared cost/QALY for alternative strategies in patients
